Project Grant R01CA307224
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $589K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85724, USA
Similar Awards
- Federal Grant Award Summary The University of Arizona received a $544,929 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. The award funds fundamental research investigating the role of estrogen receptor (ER) in regulating breast cancer cell invasion, with particular focus on how tumor microenvironment (TME) mechanical properties and estrogen interact to promote invasive...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $930,500 under the Cancer Biology Research program (CFDA 93.396) to the University of Arizona to support a seven-year project (September 10, 2025 – August 31, 2032) investigating loss of Y chromosome (LOY) in cancer development and progression. The research focuses on understanding why loss of the Y chromosome in both cancer cells and immune cells within the tumor microenvironment drives aggressive bladder cancer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...
- Federal Grant Award Summary The National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded a $661,721 Project Grant to the University of California, San Diego, effective April 1, 2026, through March 31, 2031. This award supports systematic functional mapping and interrogation of oncogenic intrinsically disordered regions (IDRs) in cancer driver proteins. The research will utilize high-throughput functional screening technologies to perform domain and residue-level...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $477,674 Project Grant to The Johns Hopkins University, effective June 1, 2026 through May 31, 2031, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). This research initiative focuses on molecular imaging of the immune-suppressive tumor microenvironment (TME) in prostate cancer and its response to immune checkpoint inhibitor (CIT) therapy. The project will employ molecular and functional imaging...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $688,073 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. The award funds computational research to reconstruct the evolutionary history of cancer metastases, led by Principal Investigator Dr. Peter Van Loo. The project develops novel molecular archeology of cancer approaches—computational methods that leverage DNA sequencing...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $354,658 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025 through July 31, 2030. This award supports fundamental research investigating subclonal P27 (CDKN1B) loss as a driver of aggressive prostate cancer, with particular focus on understanding health disparities affecting Black or African American males who experience prostate cancer mortality...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $658,423 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031, to conduct fundamental research on therapeutic targeting of PI3K gamma-positive tumor-associated macrophages (TAMs) in metastatic castration-resistant prostate cancer (MCRPC). The research aims to develop innovative therapeutics that reduce health disparities...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill a Project Grant of $627,676 under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025 through August 31, 2028. This three-year research initiative focuses on developing and validating genetically-encoded biosensors to characterize intercellular heterogeneity in cell cycle quiescence—specifically the spectrum of quiescent (dormant) states in cancer...